SpectraMedix Chosen as a 2019 QCDR for MIPS Reporting
- January 8, 2019
CMS Selects SpectraMedix as a Qualified Registry Vendor for 2019 MIPS Reporting
The SpectraMedix Platform streamlines your MIPS reporting
East Windsor, NJ – January 7, 2019 – Late last month, the Center for Medicare and Medicaid Services (CMS) approved the SpectraMedix Platform™ (previously known as eMeasures360™) as a MIPS Qualified Registry for 2019. A proven track record of success as a Qualified Registry helped to streamline the vetting process, in which SpectraMedix demonstrated its ability to calculate MIPS measures and transmit results in the required file formats.
Additionally, SpectraMedix is ONC Certified  to report all 64 eligible provider electronic clinical quality measures (eCQMs) and all 29 eligible hospital eCQMs.
“With the release of the 2019 MACRA Final Rule, six new clinician types have been added, along with additional volume threshold elements, improvement activity measures and category performance reweighting. Providers need to consider how these changes may impact their success in MIPS. Our goal is to simplify the process for our clients, by anticipating and overcoming obstacles to provide an end-to-end solution. The SpectraMedix Platform™ guides them through the entire planning and reporting process,” remarked Raj Lakhanpal, MD, FACEP, and Chief Executive Officer of SpectraMedix. “Having access to our QCDR is key to helping clients achieve their MIPS goals.”
The SpectraMedix Platform™ provides a complete solution for MIPS reporting. It enables healthcare organizations to capture patient data, calculate measures, and report results to CMS for maximizing financial incentives. The platform also provides measure drill-downs and dashboards to help leadership, providers, and analysts evaluate performance and take action to improve quality.
The SpectraMedix Platform™ offers the ability to report a broad range of quality measures including HIQR, PCMH, ACO MSSP, NCQA, CIN, HEDIS, AHRQ, and NQF. It also features a Measure Authoring Tool (MAT) to rapidly add new and custom measures as needed.
Key benefits of using the SpectraMedix Platform™ for MIPS reporting include:
- The ability to satisfy all MIPS categories and all 243 registry-based MIPS measures
- Systems to extract and harmonize claims, clinical, survey, and self-reported data
- A validation process for MIPS measure calculation
- Near real-time performance tracking to monitor and improve scores on a regular basis
Dr. Lakhanpal concluded the announcement by noting, “MIPS clients can trust SpectraMedix to use all options—including custom answers—to facilitate the data aggregation and reporting process. Anticipating change and utilizing the latest certified quality measures are significant components of the solutions we offer.”
 “This 2015 Edition Health IT Module is compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.”
SpectraMedix, founded in 2009 and headquartered in East Windsor, NJ, partners with hospitals, health systems, provider organizations, health information exchanges, and payers to improve care delivery and support their transition to value-based payment models. SpectraMedix provides expertise in multiple data gathering and reporting formats. The company has satellite offices in locations in the US and India.
609-336-7733 Ext. 308